|Clovis Oncology Inc -- USA Stock|| |
USD 64.14 0.01 0.0156%
Co-Founder, CFO, Executive VP and Secretary
Mr. Erle T. Mast is no longer Chief Financial Officer Executive Vice President of Clovis Oncology Inc. effective March 31 2016. He is one of the cofounders. Previously Mr. Mast served in the same role at Pharmion Corporationrationration beginning in 2002. From 1997 through 2002 Mr. Mast worked for Dura Pharmaceuticals Inc. and its successor Elan Corporationrationration. From 2000 to 2002 he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000 Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that Mr. Mast was a partner with Deloitte Touche LLP. Mr. Mast also serves on the board of directors of Zogenix Inc. and Receptos Inc.
Age: 51 Founder Since 2009
303 625-5000 www.clovisoncology.com
Mast received a B.Sc. in business administration from California State University Bakersfield.
Erle Mast Latest Insider Activity
The company has return on total asset (ROA)
of (25.03) %
which means that it has lost $25.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (205.06) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 282.08 M in liabilities with Debt to Equity (D/E) ratio of 94.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology Inc has Current Ratio of 3.13 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anticancer agents in the United States, Europe, and internationally. Clovis Oncology Inc (CLVS) is traded on NASDAQ in USA. It is located in COLORADO, U.S.A and employs 309 people. Clovis Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.